4x0w

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
'''Unreleased structure'''
+
==The crystal structure of mupain-1-17 in complex with murinised human uPA==
 +
<StructureSection load='4x0w' size='340' side='right' caption='[[4x0w]], [[Resolution|resolution]] 2.10&Aring;' scene=''>
 +
== Structural highlights ==
 +
<table><tr><td colspan='2'>[[4x0w]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4X0W OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4X0W FirstGlance]. <br>
 +
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=MRZ:PIPERIDINE-1-CARBOXIMIDAMIDE'>MRZ</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
 +
<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=DAL:D-ALANINE'>DAL</scene></td></tr>
 +
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4x1n|4x1n]], [[4n1p|4n1p]], [[4n1q|4n1q]], [[4n1r|4n1r]], [[4n1s|4n1s]]</td></tr>
 +
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] </span></td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4x0w FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4x0w OCA], [http://pdbe.org/4x0w PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4x0w RCSB], [http://www.ebi.ac.uk/pdbsum/4x0w PDBsum]</span></td></tr>
 +
</table>
 +
== Disease ==
 +
[[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[http://omim.org/entry/601709 601709]]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref>
 +
== Function ==
 +
[[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
Two isomeric piperidine derivatives (meta and para isomers) were used as arginine mimics in the P1 position of a cyclic peptidic inhibitor (CPAYSRYLDC) of urokinase-type plasminogen activator. The two resulting cyclic peptides showed vastly different affinities ( approximately 70 fold) to the target enzyme. X-ray crystal structure analysis showed that the two P1 residues were inserted into the S1 specificity pocket in indistinguishable manners. However, the rest of the peptides bound in entirely different ways on the surface of the enzyme, and the two peptides have different conformations, despite the highly similar sequence. These results demonstrate how the subtle difference in P1 residue can dictate the exosite interactions and the potencies of peptidic inhibitors, and highlight the importance of the P1 residue for protease inhibition. This study provides important information for the development of peptidic agents for pharmacological intervention.
-
The entry 4x0w is ON HOLD until Paper Publication
+
Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues.,Jiang L, Zhao B, Xu P, Sorensen HP, Jensen JK, Christensen A, Hosseini M, Nielsen NC, Jensen KJ, Andreasen PA, Huang M Int J Biochem Cell Biol. 2015 May;62:88-92. doi: 10.1016/j.biocel.2015.02.016., Epub 2015 Mar 2. PMID:25744057<ref>PMID:25744057</ref>
-
Authors: Jiang, L., Zhao, B., Xu, P., Andreasen, P., Huang, M.
+
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-
 
+
</div>
-
Description: The crystal structure of mupain-1-17 in complex with murinised human uPA
+
<div class="pdbe-citations 4x0w" style="background-color:#fffaf0;"></div>
-
[[Category: Unreleased Structures]]
+
== References ==
-
[[Category: Zhao, B]]
+
<references/>
 +
__TOC__
 +
</StructureSection>
 +
[[Category: U-plasminogen activator]]
[[Category: Andreasen, P]]
[[Category: Andreasen, P]]
-
[[Category: Xu, P]]
 
[[Category: Huang, M]]
[[Category: Huang, M]]
[[Category: Jiang, L]]
[[Category: Jiang, L]]
 +
[[Category: Xu, P]]
 +
[[Category: Zhao, B]]
 +
[[Category: Hydrolase inhibitor-hydrolase complex]]
 +
[[Category: Hydrolase-hydrolase inhibitor complex]]
 +
[[Category: Peptidic inhibitor]]
 +
[[Category: Serine protease]]

Revision as of 05:27, 22 October 2015

The crystal structure of mupain-1-17 in complex with murinised human uPA

4x0w, resolution 2.10Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools